

Florian A Karreth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3521073/publications.pdf>

Version: 2024-02-01

28
papers

3,488
citations

567281

15
h-index

526287

27
g-index

33
all docs

33
docs citations

33
times ranked

5136
citing authors

#	ARTICLE	IF	CITATIONS
1	A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities. <i>JID Innovations</i> , 2022, 2, 100076.	2.4	4
2	Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer. <i>American Journal of Human Genetics</i> , 2022, 109, 116-135.	6.2	3
3	Genetic tools for the stable overexpression of circular RNAs. <i>RNA Biology</i> , 2022, 19, 353-363.	3.1	7
4	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2131-2146.	7.0	36
5	Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis. <i>Cancer Research</i> , 2022, 82, 3016-3031.	0.9	2
6	Strategies to Study the Functions of Pseudogenes in Mouse Models of Cancer. <i>Methods in Molecular Biology</i> , 2021, 2324, 287-304.	0.9	1
7	Pseudogenes as Competitive Endogenous RNAs: Testing miRNA Dependency. <i>Methods in Molecular Biology</i> , 2021, 2324, 131-147.	0.9	2
8	A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFC and MYBL2. <i>Cancers</i> , 2021, 13, 1408.	3.7	16
9	A Mutational Survey of Acral Nevi. <i>JAMA Dermatology</i> , 2021, 157, 831-835.	4.1	13
10	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	16.8	90
11	Squaring the circle: circRNAs in melanoma. <i>Oncogene</i> , 2021, 40, 5559-5566.	5.9	10
12	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 149-157.	9.6	30
13	A Versatile ES Cell-Based Melanoma Mouse Modeling Platform. <i>Cancer Research</i> , 2020, 80, 912-921.	0.9	11
14	Long Non-Coding RNAs in Melanoma Development and Biology. <i>Proceedings of the Singapore National Academy of Science</i> , 2020, 14, 145-166.	0.1	1
15	A Roadmap for the Computational Prediction and Experimental Validation of Competitive Endogenous RNAs. <i>Methods in Molecular Biology</i> , 2019, 1970, 237-250.	0.9	0
16	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Scientific Reports</i> , 2017, 7, 10484.	3.3	60
17	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E536-45.	7.1	121
18	The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo. <i>Cell</i> , 2015, 161, 319-332.	28.9	293

#	ARTICLE	IF	CITATIONS
19	Aberrant ceRNA activity drives lung cancer. <i>Cell Research</i> , 2014, 24, 259-260.	12.0	41
20	Role of BRAFV600E in the First Preclinical Model of Multifocal Infiltrating Myopericytoma Development and Microenvironment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	31
21	Characterization of Dual PTEN and p53-Targeting MicroRNAs Identifies MicroRNA-638/Dnm2 as a Two-Hit Oncogenic Locus. <i>Cell Reports</i> , 2014, 8, 714-722.	6.4	49
22	Pseudogenes as Competitive Endogenous RNAs: Target Prediction and Validation. <i>Methods in Molecular Biology</i> , 2014, 1167, 199-212.	0.9	16
23	The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA. <i>Blood</i> , 2014, 124, 263-263.	1.4	2
24	ceRNA Cross-Talk in Cancer: When ce-bling Rivalries Go Awry. <i>Cancer Discovery</i> , 2013, 3, 1113-1121.	9.4	750
25	Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7154-7159.	7.1	303
26	Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs. <i>Cell</i> , 2011, 147, 344-357.	28.9	926
27	InÂVivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. <i>Cell</i> , 2011, 147, 382-395.	28.9	602
28	C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E. <i>Molecular Cell</i> , 2009, 36, 477-486.	9.7	61